Poseida Therapeutics to Present at Two Upcoming Investor Conferences

PSTX 11.11.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-18
Name of Upcoming Event:Stifel 2024 Healthcare Conference
Date of Upcoming Event:2024-12-04
Name of Upcoming Event:Piper Sandler 36th Annual Healthcare Conference
Full Press ReleaseSEC FilingsOur PSTX Tweets

About Gravity Analytica

Recent News

    Recent Filings

    • 01.21.2025 - 15-12G Securities registration termination [Section 12(g)]
    • 01.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
    • 01.13.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership

    SAN DIEGO,Nov. 11, 2024/PRNewswire/ --Poseida Therapeutics, Inc.(Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that the Company will participate in the following upcoming investor conferences:

    (PRNewsfoto/Poseida Therapeutics, Inc.)

    Stifel 2024 Healthcare ConferenceDate:Monday, November 18, 2024Time:10:20am ET

    Piper Sandler 36thAnnual Healthcare ConferenceDate:Wednesday, December 4, 2024Time:12:00pm ET

    Webcasts will be available on the Investors & Media Section of Poseida's website,www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.

    About Poseida Therapeutics, Inc.Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral transposon-based DNA delivery system, Cas-CLOVERTMSite-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more atwww.poseida.comand connect with Poseida onXandLinkedIn.

    CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-two-upcoming-investor-conferences-302301700.html

    SOURCEPoseida Therapeutics, Inc.

    Poseida Investor and Media Relations: Alex Chapman, Senior Vice President, IR & Corporate Communications, IR@poseida.com; Sarah Thailing, Senior Director, IR & Corporate Communications, PR@poseida.com

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com